Back to Oncology
OncologyvOriginal_and_ModifiedEvidence-Based

Glasgow Prognostic Score (GPS)

Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.

Clinical Input Parameters

mg/dL
Range: 0 — 50 mg/dL
g/dL
Range: 1 — 6 g/dL
Clinical Assessment
Awaiting Parameters
gps score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Glasgow Prognostic Score (GPS) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Original GPS: Score 0 (CRP ≤1.0 mg/dL AND albumin ≥3.5 g/dL), Score 1 (CRP >1.0 mg/dL OR albumin <3.5 g/dL), Score 2 (CRP >1.0 mg/dL AND albumin <3.5 g/dL). Modified GPS: Score 0 (CRP ≤1.0 mg/dL), Score 1 (CRP >1.0 mg/dL AND albumin ≥3.5 g/dL), Score 2 (CRP >1.0 mg/dL AND albumin <3.5 g/dL)

Clinical Pearls & Practice Notes

  • Most extensively validated systemic inflammation-based prognostic score
  • Validated in >60 studies with >30,000 cancer patients
  • Applicable across multiple cancer types: colorectal, hepatocellular, sarcoma, lung, renal, gastric
  • Modified GPS (mGPS) assigns intermediate score only for elevated CRP, ignoring isolated low albumin
  • Both GPS and mGPS have independent prognostic value in operable and inoperable disease
  • Can be used for patient stratification in clinical trials
  • May guide treatment intensity and palliative care decisions
  • Cost-effective as it uses routine laboratory parameters
  • Should be measured before treatment initiation
  • Serial measurements may help monitor treatment response
  • Reflects both systemic inflammatory response (CRP) and nutritional decline (albumin)
  • Higher scores associated with increased mortality and shorter survival
  • May help identify patients requiring nutritional support or anti-inflammatory interventions
  • Complements other prognostic factors like TNM staging

Evidence & Literature Citations

  1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(5):1028-1030.
  2. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540.
  3. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-163.
  4. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-2641.

Score Interpretation Ranges

GPS 00 – 0 pts

Low risk - Normal inflammation and nutrition

GPS 11 – 1 pts

Intermediate risk - Mild inflammation or nutritional compromise

GPS 22 – 2 pts

High risk - Severe inflammation and nutritional compromise

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.